FDA grants Breakthrough Device designation to Beyond Air LungFit GO for chronic NTM lung disease
Beyond Air’s LungFit GO has received FDA Breakthrough Device designation for nontuberculous mycobacterial pulmonary disease after a 15-patient pilot showed high-dose nitric oxide could be self-administered at home.